First-ever Results to be Presented from Multiple Studies Evaluating Company’s PNK Allogeneic Cell Therapy in Patients with Acute Myeloid Leukemia and Multiple Myeloma
WARREN, N.J.–(BUSINESS WIRE)–Celularity, Inc., a clinical-stage cell therapeutics company developing allogeneic cellular therapies harnessed from human placentas, today announced it will present first-ever clinical and pre-clinical results from its comprehensive...
WARREN, N.J., Aug. 31, 2018 /PRNewswire/ — Celularity, an allogeneic immuno-oncology and placental cell therapeutics company, today announced it entered into a definitive agreement to acquire CariCord, the family cord blood...
WARREN, N.J., Feb. 15, 2018 /PRNewswire/ — Celularity has been created through the contribution and acquisition of extensive intellectual property, clinical-stage assets, basic and clinical research, and product development expertise including: First proprietary...
Celularity Announces Results of Phase 1 Studies of PNK-007, an Allogeneic, Off-the-Shelf, Placental-Derived Cell Therapy, at AACR Annual Meeting 2019
First Clinical Results Evaluating Allogeneic, Off-The-Shelf, Placental-Derived Cells to be Presented by Celularity at 2019 AACR Annual Meeting
Celularity Acquires CariCord, Inc., Adds Important Biosourcing Assets, Strategic Relationship with the University of Colorado’s ClinImmune Labs
Celularity Announces $250M in Funding to Deliver Treatments for Cancer, Inflammatory and Degenerative Diseases, and Functional Regeneration